Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, Verona, Italy.
Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, Verona, Italy.
Eur J Surg Oncol. 2020 Sep;46(9):1734-1741. doi: 10.1016/j.ejso.2020.04.006. Epub 2020 Apr 13.
The pattern of nodal spread in body-tail pancreatic ductal adenocarcinoma (PDAC) has been poorly investigated. This study analyzed the characteristics of lymph node (LN) involvement and the prognostic role of nodal metastases stratified by LN stations.
All upfront distal pancreatectomies (DPs) for PDAC (2000-2017) with complete information on station 8,10,11, and 18 were included. Clinico-pathological correlates and survival were investigated using uni- and multivariable analyses.
Among 100 included patients, 28 were N0, 42 N1 and 30 N2. The median number of examined LN was 32 (IQR 26-44). Tumor size at preoperative imaging increased across N-classes. Preoperative size >27.5 mm was associated with N2 status. The frequency of nodal metastases at stations 8, 9, 10, 11, and 18 was 12.0%, 10.9%, 3.0%, 71.0%, and 19%, respectively. The pattern of LN spread was independent from primary tumor location (with tail tumors metastasizing to station 8/9 and body tumors to station 10), while it was highly associated with N-class. At multivariable analysis, tumor grading, adjuvant treatment, station 9 and 10 metastases were independent prognostic factors in node-positive patients.
In patients undergoing upfront DP for PDAC preoperative tumor size is associated with the degree of nodal spread. While station 11 was the most frequently involved, only station-9 and 10 metastases were independent prognostic factors. The site of nodal metastases was somewhat unpredictable based on tumor location. This data has potential implications for allocating patients to neoadjuvant treatment and supports the performance of routine splenectomy during DP for PDAC.
体尾部胰腺导管腺癌(PDAC)的淋巴结转移模式研究较少。本研究分析了淋巴结(LN)受累的特征,并按 LN 站分层分析了淋巴结转移的预后作用。
纳入 2000 年至 2017 年所有接受标准胰体尾切除术(DP)治疗的 PDAC 患者,且均有关于站 8、10、11 和 18 的完整信息。采用单变量和多变量分析方法研究临床病理相关性和生存情况。
100 例患者中,28 例为 N0,42 例为 N1,30 例为 N2。检查的 LN 中位数为 32(IQR 26-44)。术前影像学上的肿瘤大小随 N 分期增加而增大。术前肿瘤大小>27.5mm 与 N2 状态相关。站 8、9、10、11 和 18 的淋巴结转移频率分别为 12.0%、10.9%、3.0%、71.0%和 19%。淋巴结转移模式与原发肿瘤位置无关(尾部肿瘤转移至站 8/9,体部肿瘤转移至站 10),但与 N 分期高度相关。多变量分析显示,肿瘤分级、辅助治疗、站 9 和 10 的转移是淋巴结阳性患者的独立预后因素。
在接受标准 DP 治疗 PDAC 的患者中,术前肿瘤大小与淋巴结扩散程度相关。尽管站 11 是最常受累的部位,但只有站 9 和 10 的转移是独立的预后因素。淋巴结转移的部位在一定程度上难以根据肿瘤位置预测。这些数据对患者分配到新辅助治疗具有潜在影响,并支持在 DP 治疗 PDAC 时常规行脾切除术。